An announcement from Genfit SA ( ($GNFT) ) is now available. On September 19, 2025, GENFIT announced the discontinuation of its VS-01 program for ...

Altisource Portfolio Solutions surged in 2025 amid foreclosures, but high risk and debt make it unfit for long-term investors ...

From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the ...

GENFIT’s decision follows the occurrence of a peritonitis case reported as Serious Adverse Event (SAE) in the UNVEIL-IT® clinical trial evaluating VS-01 in patients with ACLF grades 1, 2 or 3a and ...

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...

Lockheed and Boeing's rivalry shapes air forces worldwide. This deep dive analyzes key programs and market dynamics to declare a winner.

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Natural food company Hain Celestial (NASDAQ:HAIN) in Q2 CY2025, with sales falling 13.2% year on year to $363.3 million. Its ...

Investors are pitting popular names like Ripple's XRP against up-and-coming coins like Mutuum Finance (MUTM). While XRP ...

Leveraging scale, MLC’s managed accounts cut costs for investors while offering access, diversification, and institutional-grade solutions.

So far in 2025, Chevron shares are up nearly 9% year to date, handily outperforming EPD, which has gained just 0.3%. The ...